RNA
Price
$29.77
Change
+$3.03 (+11.33%)
Updated
Apr 2 closing price
Capitalization
3.58B
40 days until earnings call
VINC
Price
$0.63
Change
+$0.06 (+10.53%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
1.41M
36 days until earnings call
Ad is loading...

RNA vs VINC

Header iconRNA vs VINC Comparison
Open Charts RNA vs VINCBanner chart's image
Avidity Biosciences
Price$29.77
Change+$3.03 (+11.33%)
Volume$3.15M
Capitalization3.58B
Vincerx Pharma
Price$0.63
Change+$0.06 (+10.53%)
Volume$2.53K
Capitalization1.41M
RNA vs VINC Comparison Chart
Loading...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VINC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RNA vs. VINC commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RNA is a StrongBuy and VINC is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (RNA: $29.77 vs. VINC: $0.57)
Brand notoriety: RNA and VINC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RNA: 216% vs. VINC: 18%
Market capitalization -- RNA: $3.58B vs. VINC: $1.41M
RNA [@Biotechnology] is valued at $3.58B. VINC’s [@Biotechnology] market capitalization is $1.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RNA’s FA Score shows that 0 FA rating(s) are green whileVINC’s FA Score has 1 green FA rating(s).

  • RNA’s FA Score: 0 green, 5 red.
  • VINC’s FA Score: 1 green, 4 red.
According to our system of comparison, VINC is a better buy in the long-term than RNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RNA’s TA Score shows that 3 TA indicator(s) are bullish while VINC’s TA Score has 4 bullish TA indicator(s).

  • RNA’s TA Score: 3 bullish, 6 bearish.
  • VINC’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, VINC is a better buy in the short-term than RNA.

Price Growth

RNA (@Biotechnology) experienced а -7.11% price change this week, while VINC (@Biotechnology) price change was -0.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.26%. For the same industry, the average monthly price growth was -7.43%, and the average quarterly price growth was -11.99%.

Reported Earning Dates

RNA is expected to report earnings on May 13, 2025.

VINC is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-5.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($3.58B) has a higher market cap than VINC($1.41M). RNA YTD gains are higher at: 2.373 vs. VINC (-89.060). VINC has higher annual earnings (EBITDA): -27.1M vs. RNA (-376.16M). RNA has more cash in the bank: 1.5B vs. VINC (80.9M). VINC has less debt than RNA: VINC (1.64M) vs RNA (6.8M). RNA has higher revenues than VINC: RNA (10.9M) vs VINC (0).
RNAVINCRNA / VINC
Capitalization3.58B1.41M253,650%
EBITDA-376.16M-27.1M1,388%
Gain YTD2.373-89.060-3%
P/E RatioN/AN/A-
Revenue10.9M0-
Total Cash1.5B80.9M1,855%
Total Debt6.8M1.64M415%
TECHNICAL ANALYSIS
Technical Analysis
RNAVINC
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 10 days ago
86%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VINC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ETAMX14.22N/A
N/A
Eventide Balanced Fund Class A
NAESX106.63N/A
N/A
Vanguard Small Cap Index Inv
NRIIX21.58N/A
N/A
Nuveen Real Asset Income I
GGINX12.87N/A
N/A
Goldman Sachs Global Infras Inv
AFDGX49.51N/A
N/A
American Century Large Cap Equity R5

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
+11.33%
DYN - RNA
45%
Loosely correlated
+7.37%
ACLX - RNA
44%
Loosely correlated
+10.76%
CRNX - RNA
44%
Loosely correlated
+2.51%
RYTM - RNA
43%
Loosely correlated
+3.92%
RVMD - RNA
43%
Loosely correlated
+2.91%
More

VINC and

Correlation & Price change

A.I.dvisor indicates that over the last year, VINC has been loosely correlated with APVO. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if VINC jumps, then APVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VINC
1D Price
Change %
VINC100%
+8.61%
APVO - VINC
33%
Loosely correlated
-13.96%
RNA - VINC
31%
Poorly correlated
-9.42%
VNDA - VINC
30%
Poorly correlated
-1.96%
IOVA - VINC
30%
Poorly correlated
-2.40%
CRIS - VINC
29%
Poorly correlated
-30.48%
More